false
0001653477
0001653477
2026-03-26
2026-03-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d)
of the Securities
Exchange Act of 1934
March 26, 2026
Date
of Report (date of earliest event reported)

INGEVITY
CORPORATION
(Exact
name of registrant as specified in its charter)
| Delaware | |
001-37586 | |
47-4027764 |
| (State or other jurisdiction of incorporation or organization) | |
(Commission File Number) | |
(I.R.S. Employer Identification No.) |
| 4920 OHear Avenue, Suite 400 | |
North Charleston | |
South Carolina | |
29405 |
| | |
(Address of principal executive offices) | |
| |
(Zip code) |
Registrant’s telephone
number, including area code: 843-740-2300
Not
Applicable
(Former
name or former address, if changed since last report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
| Common Stock ($0.01 par value) |
|
NGVT |
|
New York Stock Exchange |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
¨
Emerging growth company
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨
Item 1.01. ENTRY INTO
A MATERIAL DEFINITIVE AGREEMENT
On March 26, 2026 (the “Closing Date”),
Ingevity Corporation (the “Company”), Ingevity Holdings SRL (“Holdings”), Ingevity UK Ltd (the “UK
Borrower”), the other loan parties party thereto, the lenders party thereto, the issuing banks party thereto and JPMorgan Chase
Bank, N.A., as administrative agent (the “Administrative Agent”), collateral agent and swingline lender, entered into
that certain Second Amendment and Restatement Agreement (the “Amendment”), which amends and restates the Amended and
Restated Credit Agreement, dated as of June 23, 2022 (the “Existing Credit Agreement,” and as amended and restated
by the Amendment, the “Second Amended and Restated Credit Agreement”), by and among the Company, Holdings, the UK Borrower,
the lenders from time to time party thereto and the Administrative Agent.
The
Amendment amends and restates the Existing Credit Agreement to, among other things, (a) extend the maturity date of the Company’s
revolving credit facility to the date that is five years after the Closing Date, (b) decrease the aggregate amount of the commitments
thereunder from $1 billion to $750 million and (c) effect certain other amendments. Borrowings under the revolving credit facility
bear interest at a rate per annum equal to, at the Company’s option, either (a) the applicable term benchmark rate, subject to a
0.00% floor, or (b) a base rate, in each case, plus an applicable margin of 1.00% to 1.75% for term benchmark loans and 0.00% to 0.75%
for base rate loans. The Second Amended and Restated Credit Agreement contains certain customary affirmative and negative covenants, representations
and warranties and events of default (subject in certain cases to customary grace and cure periods).
On the Closing Date, the Company repaid all of
its outstanding revolving loans in an aggregate principal amount of $512.1 million.
The foregoing summary of the Amendment does not
purport to be complete and is subject to, qualified in its entirety by, the full text of the Amendment, which is filed as Exhibit 10.1
to this Current Report on Form 8-K and is incorporated herein by reference.
Item 2.03. Creation of
a direct financial obligation or an obligation under an off-balance sheet arrangement of a registrant
The information in Item 1.01 above is incorporated
by reference into this Item 2.03.
Item 9.01. Financial Statements and Exhibits
(d)
Exhibits
Exhibit
No. |
|
Description |
| 10.1 |
|
Second
Amendment and Restatement Agreement, dated as of March 26, 2026, among Ingevity Corporation, Ingevity Holdings SRL, Ingevity UK Ltd,
the other loan parties party thereto, JPMorgan Chase Bank, N.A., as the administrative agent, and the lenders party thereto |
| |
|
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
|
INGEVITY CORPORATION
(Registrant) |
| |
|
|
| |
By: |
/s/
Mary Dean Hall |
| |
|
Mary
Dean Hall |
| |
|
Executive
Vice President and Chief Financial Officer |
| Date: March
30, 2026 |
|
|